Filana Therapeutics Expects Patient Screening In Phase 2a Study Of Simufilam In TSC-Related Epilepsy To Begin By Q1 2027, Following FDA Lift Of Clinical Hold In September
Share
Why It Matters
Filana got permission to test a new medicine for epilepsy. Patients will start trying it in early 2027, which shows the company is moving forward.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.